Latest News
Mirum Pharmaceuticals, Inc.
- Mirum Pharmaceuticals, Inc. Estimates – BOATS:MIRM
- Form 4 Mirum Pharmaceuticals Inc: Jolanda Howe (SVP, GLOBAL CONTROLLER) For: 16 October
- Mirum Pharmaceuticals' LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases
- Baird reiterates Mirum Pharmaceuticals stock rating on trial success By Investing.com
- TD Cowen reiterates Mirum Pharmaceuticals stock Buy rating at $140 By Investing.com
- Mirum on its way to 3rd rare liver indication for Livmarli
- [Press release] Mirum Pharmaceuticals announces primary endpoint met in Phase 3 AZURE-1 study of brelovitug in chronic hepatitis delta virus
- Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Vir
- Mirum's liver infection drug lowers virus levels in late-stage study
- US FDA approves Mirum's drug for rare bone disorder
- Mirum bags FDA approval for ultra-rare bone lesion disorder, heating up rivalry with Regeneron
- Mirum Pharmaceuticals wins Bay Area's 14th drug approval this year
Headlines from the last 30 days, linking to the original publishers. See all market news →